BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elevar Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Elevar Therapeutics\, Inc.'s drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07682272-2014@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Apatinib: Phase 2 readout est. (NCT07682272)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Trial 
 of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatm
 ent of Resectable Hepatocellular Carcinoma\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07682
 272
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359820-10824@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lyrfigtu (lirafugratinib): Phase 2 readout est. (NCT07359820)
DESCRIPTION:Lyrfigtu (lirafugratinib)\, phase 2.\nStudy: A Study of Lirafug
 ratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lirafugratinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07359820
URL:https://assetmemo.bio/drug/lirafugratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
